Romiplostim biosimilar - Eris Lifesciences
Alternative Names: Recombinant human thrombopoietin - Eris Lifesciences; rhTPO - Eris LifesciencesLatest Information Update: 28 Jul 2024
At a glance
- Originator Eris Lifesciences
- Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic thrombocytopenic purpura
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Idiopathic thrombocytopenic purpura in India (SC, Injection)
- 08 Jun 2020 Eris Lifesciences plans a phase III trial for Idiopathic thrombocytopenic purpura in India (SC)(CTRI/2020/06/025707)